Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2018 December;60(4) > Panminerva Medica 2018 December;60(4):174-84

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Panminerva Medica 2018 December;60(4):174-84

DOI: 10.23736/S0031-0808.18.03542-5

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Therapy for relapsed multiple myeloma

Mohammed A. ALJAMA, M. Hasib SIDIQI, David DINGLI

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA



Despite significant progress in our understanding and the development of novel therapies, most patients with multiple myeloma will experience relapse of their disease. Therapy of relapsed myeloma has improved due to the availability of novel agents that are highly active against the disease. However, the selection of therapy can be challenging due to the emergence of toxicities, comorbidities and frailty. In the following we discuss our approach to the treatment of the patient with relapsed myeloma.


KEY WORDS: Recurrence - Multiple myeloma - Therapeutics

top of page